GO:2000490 negative regulation of hepatic stellate cell activation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:2000490 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of hepatic stellate cell (HSC) activation, a key event in liver fibrosis.
• HSC activation is driven by metabolic reprogramming, autophagy, and signaling pathways such as IGF1R/EGR1/PDGF-BB, Notch/Jag1, and O-GlcNAcylation.
• Negative regulation of HSC activation can be achieved by promoting ferroptosis, inhibiting fibrogenic signaling, or modulating metabolic enzymes like LONP1.
• Key genes involved include ACTA2, COL1A1, PDGFRB, TGFB1, and metabolic regulators such as LONP1 and OGT.
• Dysregulation of this process contributes to liver fibrosis, cirrhosis, and hepatocellular carcinoma, making it a therapeutic target.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of genes that negatively regulate HSC activation.
Description
Hepatic stellate cells (HSCs) are resident perisinusoidal cells that, upon liver injury, undergo activation into myofibroblast-like cells, a process central to liver fibrosis. The Gene Ontology term GO:2000490, negative regulation of hepatic stellate cell activation, encompasses any process that stops, prevents, or reduces the frequency, rate, or extent of this activation. Understanding the molecular mechanisms that restrain HSC activation is critical for developing anti-fibrotic therapies. Recent studies have identified diverse regulators, including metabolic enzymes, signaling pathways, and epigenetic modifiers, that negatively regulate HSC activation. This article synthesizes current knowledge on GO:2000490, highlighting key genes, regulatory mechanisms, disease implications, and research methodologies, with a focus on CRISPR-based approaches for functional validation.
negative regulation of hepatic stellate cell activation At A Glance
| GO ID | GO:2000490 |
|---|---|
| GO term | negative regulation of hepatic stellate cell activation |
| Ontology | biological_process |
| Synonym | none |
| Major function | Suppression of HSC activation, preventing or reducing liver fibrosis |
| Related processes | HSC activation, liver fibrosis, ferroptosis, autophagy, metabolic reprogramming |
| Key regulators | LONP1, OGT, DNMT1, SCARA5, GPX4, IGF2BP3, Notch/Jag1, PDGF-BB |
| Disease relevance | Liver fibrosis, cirrhosis, hepatocellular carcinoma |
What Is GO:2000490?
GO:2000490 is a biological process term defined as any process that stops, prevents, or reduces the frequency, rate, or extent of hepatic stellate cell activation. In other words, it includes all molecular and cellular events that keep HSCs in a quiescent state or reverse their activated phenotype, thereby limiting fibrogenesis.
Why Is negative regulation of hepatic stellate cell activation Important in Cell Biology?
GO:2000490 is crucial because HSC activation is the central driver of liver fibrosis, a condition that can progress to cirrhosis and hepatocellular carcinoma. Identifying negative regulators of HSC activation offers potential therapeutic targets to halt or reverse fibrosis. Moreover, understanding these regulatory mechanisms provides insights into liver homeostasis and regeneration.
• HSC activation is a hallmark of chronic liver disease and fibrosis.
• Negative regulation of HSC activation can prevent fibrosis progression.
• Metabolic enzymes like LONP1 and OGT modulate HSC activation and fibrosis.
• Ferroptosis inducers, such as baicalein, promote HSC ferroptosis via DNMT1/SCARA5/GPX4 axis, negatively regulating activation.
• The IGF2BP3/Notch/Jag1 pathway regulates HSC ferroptosis and activation.
• O-GlcNAcylation inhibits HSC activation, linking nutrient sensing to fibrosis.
• Targeting negative regulators could lead to novel anti-fibrotic therapies.
• CRISPR screens can identify novel negative regulators of HSC activation.
• Dysregulation of this process is implicated in MASH-induced liver fibrosis.
• Understanding GO:2000490 aids in developing personalized treatments for liver fibrosis.
What Happens During negative regulation of hepatic stellate cell activation?
Metabolic Reprogramming and HSC Commitment
In simple terms: Changes in how cells use energy can stop HSCs from becoming activated.
Trajectory analysis of HSC differentiation reveals that metabolic regulation controls cell commitment and fibrosis. Specific metabolic pathways, including those involving LONP1, influence HSC activation state. Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels, indicating that LONP1 negatively regulates HSC activation.
Ferroptosis-Mediated Suppression
In simple terms: Inducing a type of cell death called ferroptosis can eliminate activated HSCs.
Ferroptosis is an iron-dependent form of cell death that can negatively regulate HSC activation. Baicalein facilitates HSC ferroptosis via the DNMT1/SCARA5/GPX4 axis, thereby inhibiting activation. Similarly, the IGF2BP3/Notch/Jag1 pathway regulates HSC ferroptosis in liver fibrosis, with Notch signaling promoting ferroptosis and negatively regulating activation.
Signaling Pathways Inhibiting Activation
In simple terms: Certain molecular signals act as brakes on HSC activation.
The IGF1R/EGR1/PDGF-BB signaling pathway, driven by hepatocyte Ninjurin2, promotes HSC activation; thus, negative regulators of this pathway can inhibit activation. O-GlcNAcylation, a post-translational modification, inhibits HSC activation, linking nutrient sensing to fibrosis suppression. Fibroblast activation protein (FAP) activates macrophages and promotes liver inflammation and fibrosis, so its inhibition may negatively regulate HSC activation.
Autophagy and Senescence
In simple terms: Cellular cleanup processes can influence whether HSCs stay activated.
Autophagy drives fibroblast senescence through MTORC2 regulation, suggesting that autophagy modulation can affect HSC activation state. Senescence of activated HSCs is associated with reduced fibrosis, indicating that autophagy-related pathways may negatively regulate HSC activation.
Key Genes Involved in GO:2000490 negative regulation of hepatic stellate cell activation
The following genes and proteins have been implicated in the negative regulation of hepatic stellate cell activation, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LONP1 | Mitochondrial protease; decreased expression elevates orotic acid, exacerbating fibrosis | Metabolic regulator of HSC activation; target for MASH fibrosis |
| OGT | O-GlcNAc transferase; mediates O-GlcNAcylation that inhibits HSC activation | Nutrient-sensing pathway; potential therapeutic target |
| DNMT1 | DNA methyltransferase; regulates SCARA5/GPX4 axis in ferroptosis | Epigenetic regulator of HSC ferroptosis |
| SCARA5 | Scavenger receptor; involved in ferroptosis regulation | Ferroptosis mediator in HSCs |
| GPX4 | Glutathione peroxidase 4; key ferroptosis inhibitor | Target for inducing HSC ferroptosis |
| IGF2BP3 | RNA-binding protein; regulates Notch/Jag1 pathway | Modulates HSC ferroptosis and activation |
| NOTCH1 | Notch receptor; promotes HSC ferroptosis | Negative regulator of HSC activation |
| JAG1 | Notch ligand; activates Notch signaling | Involved in HSC ferroptosis |
| NINJ2 | Ninjurin2; hepatocyte-derived factor promoting HSC activation via IGF1R/EGR1/PDGF-BB | Its inhibition may negatively regulate HSC activation |
| IGF1R | Insulin-like growth factor 1 receptor; mediates signaling to HSCs | Target for blocking fibrogenic signaling |
| EGR1 | Early growth response 1; transcription factor downstream of IGF1R | Regulates PDGF-BB expression |
| PDGFB | Platelet-derived growth factor B; potent HSC mitogen | Key driver of HSC activation; inhibition suppresses fibrosis |
| FAP | Fibroblast activation protein; activates macrophages and promotes fibrosis | Potential target for negative regulation |
| MTOR | Mechanistic target of rapamycin; regulates autophagy and senescence | Modulates HSC activation via MTORC2 |
| ACTA2 | Alpha-smooth muscle actin; marker of activated HSCs | Readout of HSC activation state |
| COL1A1 | Collagen type I alpha 1; major extracellular matrix component | Marker of fibrosis; negatively regulated by anti-fibrotic processes |
| TGFB1 | Transforming growth factor beta 1; profibrotic cytokine | Its inhibition negatively regulates HSC activation |
| PDGFRB | Platelet-derived growth factor receptor beta; mediates HSC proliferation | Target for anti-fibrotic therapy |
How Is negative regulation of hepatic stellate cell activation Regulated?
The negative regulation of HSC activation is controlled by a complex network of signaling pathways, metabolic sensors, and epigenetic modifiers. O-GlcNAcylation, mediated by OGT, acts as a nutrient-sensing brake on HSC activation. The LONP1-orotic acid axis links mitochondrial function to HSC quiescence. Ferroptosis pathways, regulated by DNMT1/SCARA5/GPX4 and IGF2BP3/Notch/Jag1, actively suppress activated HSCs. Additionally, autophagy and MTORC2 signaling influence HSC senescence and activation state. These regulatory mechanisms are potential targets for therapeutic intervention.
negative regulation of hepatic stellate cell activation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LONP1 | MASH-induced liver fibrosis | Lonp1 knockout or overexpression in HSCs; MASH mouse model |
| OGT | Liver fibrosis; O-GlcNAcylation inhibits HSC activation | Ogt conditional knockout in HSCs; CCl4 fibrosis model |
| DNMT1 | HSC ferroptosis; fibrosis | Dnmt1 knockout in HSCs; baicalein treatment |
| IGF2BP3 | HSC ferroptosis; liver fibrosis | Igf2bp3 knockout or overexpression; Notch/Jag1 modulation |
| FAP | Liver inflammation and fibrosis | Fap knockout mice; macrophage co-culture |
Liver Fibrosis and Cirrhosis
Hepatic stellate cell activation is the central event in liver fibrosis, which can progress to cirrhosis. Negative regulation of HSC activation is therefore a key therapeutic strategy. Studies have shown that enhancing LONP1 expression or inhibiting the IGF1R/EGR1/PDGF-BB pathway reduces fibrosis in models of MASH. Ferroptosis inducers like baicalein also attenuate fibrosis by promoting HSC ferroptosis.
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
MASH is a leading cause of liver fibrosis. Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels, highlighting the role of metabolic regulators in negatively controlling HSC activation. Targeting these pathways may offer new treatments for MASH fibrosis.
Hepatocellular Carcinoma (HCC)
Liver fibrosis and cirrhosis are major risk factors for HCC. Fibroblast activation protein (FAP) activates macrophages and promotes parenchymal liver inflammation and fibrosis, contributing to a pro-tumorigenic microenvironment. Negative regulation of HSC activation may therefore reduce HCC risk by limiting fibrosis.
From negative regulation of hepatic stellate cell activation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate HSC activation? | CRISPR knockout of gene X in primary HSCs or LX-2 cells, followed by activation assays |
| Does a specific point mutation in gene Y affect its anti-fibrotic function? | CRISPR point mutation knock-in in HSCs; compare to wild-type |
| Does overexpression of gene Z inhibit HSC activation? | CRISPR activation (CRISPRa) or lentiviral overexpression in HSCs |
| Does tagging of protein W alter its localization or function? | CRISPR knock-in of fluorescent or epitope tag; imaging and co-IP |
| Which metabolic pathways regulate HSC commitment? | CRISPR library screening in HSCs under fibrogenic stimuli |
| Does O-GlcNAcylation of protein V inhibit HSC activation? | CRISPR knock-in of O-GlcNAc-deficient mutant; OGT manipulation |
How to Study the negative regulation of hepatic stellate cell activation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify negative regulators of HSC activation |
| ATAC-seq | Chromatin accessibility | Discover regulatory elements in HSC activation |
| Proteomics | Protein abundance and modifications | Quantify O-GlcNAcylation and signaling proteins |
| CRISPR knockout screen | Loss-of-function phenotypes | Identify genes whose knockout enhances HSC activation |
| CRISPR activation screen | Gain-of-function phenotypes | Find genes whose overexpression inhibits activation |
| Lipid peroxidation assay | Ferroptosis levels | Assess HSC ferroptosis induction |
| Immunofluorescence | Protein localization and expression | Detect ACTA2 and COL1A1 in activated HSCs |
| Western blot | Protein expression and phosphorylation | Validate signaling changes (e.g., PDGFRB) |
Transcriptomic and Epigenomic Profiling
RNA-seq and ATAC-seq can identify genes and regulatory elements that change during HSC activation and its negative regulation. Trajectory analysis of HSC differentiation reveals metabolic regulation of cell commitment. These methods help pinpoint candidate negative regulators for functional validation.
Proteomics and Post-Translational Modification Analysis
Mass spectrometry-based proteomics can quantify protein expression and modifications such as O-GlcNAcylation, which inhibits HSC activation. Phosphoproteomics can reveal signaling changes in pathways like IGF1R/EGR1/PDGF-BB.
Functional Genomics with CRISPR Screens
Genome-wide CRISPR knockout or activation screens in HSCs can identify novel negative regulators of activation. Such screens have been used to uncover metabolic regulators of HSC commitment. Hits can be validated individually using targeted CRISPR models.
Imaging and Ferroptosis Assays
Live-cell imaging of lipid peroxidation and iron accumulation can monitor ferroptosis in HSCs, a process that negatively regulates activation. Fluorescent reporters for GPX4 or SCARA5 can be used to assess pathway activity.
How CRISPR Can Be Used to Study GO:2000490 negative regulation of hepatic stellate cell activation
Knockout
CRISPR knockout of candidate negative regulators in HSCs or LX-2 cells can determine whether loss of function enhances HSC activation. For example, knocking out LONP1 may exacerbate fibrosis markers. Knockout of OGT would reduce O-GlcNAcylation and potentially increase activation.
Point Mutation
CRISPR point mutation knock-in can model specific amino acid changes that affect protein function. For instance, mutating O-GlcNAcylation sites on a target protein can test whether that modification is required for inhibiting HSC activation. Point mutations in LONP1 catalytic domain can dissect its protease activity in fibrosis.
Knock-in
CRISPR knock-in of reporters or tags (e.g., GFP, HA) allows tracking of proteins like GPX4 or SCARA5 during HSC activation and ferroptosis. Knock-in of a fluorescent reporter under the ACTA2 promoter can monitor activation state in live cells.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can test whether increasing levels of a candidate gene inhibits HSC activation. Overexpression of LONP1 or OGT may suppress fibrogenic markers. This approach is useful for validating gain-of-function phenotypes.
How EDITGENE Supports negative regulation of hepatic stellate cell activation Research
Researchers studying negative regulation of hepatic stellate cell activation-related genes often need to determine whether a candidate gene is causally involved in suppressing HSC activation or fibrosis. EDITGENE provides comprehensive CRISPR-based services to enable such functional studies.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of hepatic stellate cell activation research.
Frequently Asked Questions About negative regulation of hepatic stellate cell activation
What is GO:2000490?
GO:2000490 is a Gene Ontology term for any biological process that stops, prevents, or reduces the frequency, rate, or extent of hepatic stellate cell activation.
What genes are involved in negative regulation of hepatic stellate cell activation?
Key genes include LONP1, OGT, DNMT1, SCARA5, GPX4, IGF2BP3, NOTCH1, JAG1, and others that modulate HSC activation and ferroptosis.
How does O-GlcNAcylation inhibit hepatic stellate cell activation?
O-GlcNAcylation, mediated by OGT, acts as a nutrient-sensing modification that suppresses HSC activation, as shown in studies linking it to reduced fibrosis.
What is the role of ferroptosis in negative regulation of HSC activation?
Ferroptosis is an iron-dependent cell death that can eliminate activated HSCs. Pathways such as DNMT1/SCARA5/GPX4 and IGF2BP3/Notch/Jag1 promote ferroptosis and thereby negatively regulate activation.
How can CRISPR be used to study negative regulation of HSC activation?
CRISPR knockout, point mutation, knock-in, and overexpression models allow functional validation of candidate genes in HSCs, determining whether they suppress activation.
What diseases are associated with dysregulation of HSC activation?
Liver fibrosis, cirrhosis, and hepatocellular carcinoma are major diseases linked to HSC activation and its negative regulation.
What is the role of LONP1 in liver fibrosis?
LONP1 is a mitochondrial protease; decreased expression exacerbates MASH-induced liver fibrosis via elevated orotic acid, indicating it negatively regulates HSC activation.
How does the IGF1R/EGR1/PDGF-BB pathway affect HSCs?
This pathway, driven by hepatocyte Ninjurin2, promotes HSC activation; thus, inhibiting it can negatively regulate activation and reduce fibrosis.
What experimental models are used to study negative regulation of HSC activation?
Common models include primary HSCs, LX-2 cells, CRISPR-engineered cell lines, and mouse models of fibrosis (e.g., CCl4, MASH diet).
What methods identify negative regulators of HSC activation?
CRISPR screens, RNA-seq, ATAC-seq, proteomics, and ferroptosis assays are key methods to discover and validate negative regulators.
Conclusion
GO:2000490, negative regulation of hepatic stellate cell activation, is a critical biological process that counteracts liver fibrosis. Advances in understanding metabolic, epigenetic, and signaling mechanisms have revealed numerous negative regulators, offering promising therapeutic targets. CRISPR-based models and functional genomics are indispensable for dissecting these pathways and translating findings into clinical applications.
References
- 1. Wang Y et al.. 2023. Hepatocyte Ninjurin2 promotes hepatic stellate cell activation and liver fibrosis through the IGF1R/EGR1/PDGF-BB signaling pathway.. Metabolism 140:155380 PMID: 36549436
- 2. Xu D et al.. 2026. Decreased LONP1 expression exacerbates MASH-induced liver fibrosis via elevated orotic acid levels.. J Hepatol 84(1):165-180 PMID: 40784490
- 3. Li M et al.. 2025. Baicalein facilitates hepatic stellate cell ferroptosis via the DNMT1/SCARA5/GPX4 axis.. Phytomedicine 149:157554 PMID: 41270385
- 4. Bernard M et al.. 2020. Autophagy drives fibroblast senescence through MTORC2 regulation.. Autophagy 16(11):2004-2016 PMID: 31931659
- 5. Martínez García de la Torre RA et al.. 2025. Trajectory analysis of hepatic stellate cell differentiation reveals metabolic regulation of cell commitment and fibrosis.. Nat Commun 16(1):1489 PMID: 39929812
- 6. Yang AT et al.. 2023. Fibroblast Activation Protein Activates Macrophages and Promotes Parenchymal Liver Inflammation and Fibrosis.. Cell Mol Gastroenterol Hepatol 15(4):841-867 PMID: 36521660
- 7. Li X et al.. 2024. The IGF2BP3/Notch/Jag1 pathway: A key regulator of hepatic stellate cell ferroptosis in liver fibrosis.. Clin Transl Med 14(8):e1793 PMID: 39113232
- 8. Li R et al.. 2021. O-GlcNAcylation inhibits hepatic stellate cell activation.. J Gastroenterol Hepatol 36(12):3477-3486 PMID: 34547820
